Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma

Figure 2

SOX2 expression in primary tumors and corresponding metastatic lymph nodes. (A) SOX2 is expressed in a higher percentage of metastatic lymph nodes as compared to primary tumors; (B) Development of SOX2 expression in lymph nodes in comparison to the corresponding metastatic primary tumor investigated in 18 samples. Positive SOX2 expression was detected in lymph node metastases originating from both SOX2 positive or negative primary tumors while no loss of SOX2 positivity was observed during progression from primary tumor to metastasis (C) Representative immunohistochemical staining of SOX2 in a primary tumor and the corresponding lymph node. Pictures were taken with 200X magnification.

Back to article page